TPO and autoimmune thrombocytopenic purpura: Recombinant human thrombopoietin (rhTPO), a glycosylated full-length peptide TPO produced by 3SBIO (Shenyang, China), has shown a high response rate (60.3%–66.7%) in corticosteroid-resistant or relapsed ITP patients (18–21).